13 results on '"Guarneri V"'
Search Results
2. OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
3. 21P Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study
4. P1.15-06 Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis
5. EP08.01-012 First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
6. EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World
7. MA07.01 Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression And Early Death in Advanced Non-Small Cell Lung Cancer
8. 51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features
9. 149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
10. 119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts)
11. 181P Multicenter real-world study (RWS) on efficacy and early discontinuation predictors in non-small cell lung cancer (NSCLC) patients (pts) receiving nivolumab
12. 164P Immune cells distribution and spatial relationship within microenvironment as predictive biomarkers of benefit in extended stage small cell lung cancer patients receiving atezolizumab plus carboplatin and etoposide as first-line treatment
13. PUB038 Prognostic Impact of FOXP3-Positive Tumor Infiltrating Lymphocytes in Small-Cell Lung Cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.